163 related articles for article (PubMed ID: 22159045)
1. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations.
da Costa RF; Freire VN; Bezerra EM; Cavada BS; Caetano EW; de Lima Filho JL; Albuquerque EL
Phys Chem Chem Phys; 2012 Jan; 14(4):1389-98. PubMed ID: 22159045
[TBL] [Abstract][Full Text] [Related]
2. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Istvan ES
Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
[TBL] [Abstract][Full Text] [Related]
3. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
4. Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Sarver RW; Bills E; Bolton G; Bratton LD; Caspers NL; Dunbar JB; Harris MS; Hutchings RH; Kennedy RM; Larsen SD; Pavlovsky A; Pfefferkorn JA; Bainbridge G
J Med Chem; 2008 Jul; 51(13):3804-13. PubMed ID: 18540668
[TBL] [Abstract][Full Text] [Related]
5. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
6. Binding thermodynamics of statins to HMG-CoA reductase.
Carbonell T; Freire E
Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575
[TBL] [Abstract][Full Text] [Related]
7. On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme.
Leopoldini M; Malaj N; Toscano M; Sindona G; Russo N
J Agric Food Chem; 2010 Oct; 58(19):10768-73. PubMed ID: 20843083
[TBL] [Abstract][Full Text] [Related]
8. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
da Silva VB; Taft CA; Silva CH
J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae.
Feng L; Zhou L; Sun Y; Gui J; Wang X; Wu P; Wan J; Ren Y; Qiu S; Wei X; Li J
Bioorg Med Chem; 2011 Jun; 19(11):3512-9. PubMed ID: 21550257
[TBL] [Abstract][Full Text] [Related]
10. Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies.
Dinesh N; Pallerla DS; Kaur PK; Kishore Babu N; Singh S
Microb Pathog; 2014 Jan; 66():14-23. PubMed ID: 24239940
[TBL] [Abstract][Full Text] [Related]
11. Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies.
Fong CW
Eur J Med Chem; 2014 Oct; 85():661-74. PubMed ID: 25128668
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
Thilagavathi R; Kumar R; Aparna V; Sobhia ME; Gopalakrishnan B; Chakraborti AK
Bioorg Med Chem Lett; 2005 Feb; 15(4):1027-32. PubMed ID: 15686906
[TBL] [Abstract][Full Text] [Related]
13. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone.
Pak VV; Koo M; Kim MJ; Yun L; Kwon DY
Bioorg Med Chem; 2008 Feb; 16(3):1309-18. PubMed ID: 17977732
[TBL] [Abstract][Full Text] [Related]
14. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
Karthik MV; Satya Deepak MV; Shukla P
Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
16. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.
Islam B; Sharma C; Adem A; Aburawi E; Ojha S
Drug Des Devel Ther; 2015; 9():4943-51. PubMed ID: 26357462
[TBL] [Abstract][Full Text] [Related]
17. Statin inhibition of HMG-CoA reductase: a 3-dimensional view.
Istvan E
Atheroscler Suppl; 2003 Mar; 4(1):3-8. PubMed ID: 12714031
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM
J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542
[TBL] [Abstract][Full Text] [Related]
19. Aromatic interactions in the binding of ligands to HMGCoA reductase.
Kee EA; Livengood MC; Carter EE; McKenna M; Cafiero M
J Phys Chem B; 2009 Nov; 113(44):14810-5. PubMed ID: 19863142
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design and screen of novel inhibitors for class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae.
Li D; Gui J; Li Y; Feng L; Han X; Sun Y; Sun T; Chen Z; Cao Y; Zhang Y; Zhou L; Hu X; Ren Y; Wan J
J Chem Inf Model; 2012 Jul; 52(7):1833-41. PubMed ID: 22725250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]